Compare RLX Technology Inc (RLX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs TG Therapeutics Inc — how do they compare? RLX Technology Inc trades at $2.03 (market cap $2.52B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 3.3× RLX Technology Inc's market cap, and RLX Technology Inc pays a 4.85% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RLX | TGTX | |
|---|---|---|
Market Cap | $2.52B | $8.26B |
Sector | Technology | Health |
52-Week High | $2.73 | $59.06 |
52-Week Low | $1.79 | $26.39 |
Enterprise Value | $1.15B | $8.50B |
Dividend Yield | 4.85% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
